UY34315A - ?uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas ? - Google Patents

?uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas ?

Info

Publication number
UY34315A
UY34315A UY0001034315A UY34315A UY34315A UY 34315 A UY34315 A UY 34315A UY 0001034315 A UY0001034315 A UY 0001034315A UY 34315 A UY34315 A UY 34315A UY 34315 A UY34315 A UY 34315A
Authority
UY
Uruguay
Prior art keywords
hypogonadism
treatment
related diseases
aromatase inhibitor
aromatase
Prior art date
Application number
UY0001034315A
Other languages
English (en)
Spanish (es)
Inventor
Taylor Ann
Lloyd B Klickstein
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46846026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34315(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY34315A publication Critical patent/UY34315A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833Encapsulating processes; Filling of capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06Anabolic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UY0001034315A 2011-09-08 2012-09-10 ?uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas ? UY34315A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161532459P 2011-09-08 2011-09-08
US201261638588P 2012-04-26 2012-04-26

Publications (1)

Publication Number Publication Date
UY34315A true UY34315A (es) 2013-04-30

Family

ID=46846026

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034315A UY34315A (es) 2011-09-08 2012-09-10 ?uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas ?

Country Status (31)

Country Link
US (4) US9370505B2 (OSRAM)
EP (2) EP2753312B1 (OSRAM)
JP (2) JP6051467B2 (OSRAM)
KR (3) KR20180030254A (OSRAM)
CN (2) CN103796644B (OSRAM)
AR (1) AR087790A1 (OSRAM)
AU (2) AU2012304693B2 (OSRAM)
BR (2) BR112014005434B1 (OSRAM)
CA (2) CA2846884C (OSRAM)
CL (1) CL2014000552A1 (OSRAM)
CY (2) CY1118461T1 (OSRAM)
DK (2) DK2753313T3 (OSRAM)
ES (2) ES2613667T3 (OSRAM)
HR (2) HRP20170002T1 (OSRAM)
HU (2) HUE031435T2 (OSRAM)
IL (1) IL231234A (OSRAM)
IN (1) IN2014DN01619A (OSRAM)
LT (2) LT2753313T (OSRAM)
MX (2) MX360315B (OSRAM)
PE (1) PE20141584A1 (OSRAM)
PH (1) PH12014500435A1 (OSRAM)
PL (2) PL2753313T3 (OSRAM)
PT (2) PT2753312T (OSRAM)
RU (2) RU2617510C2 (OSRAM)
SG (2) SG10201607503WA (OSRAM)
SI (2) SI2753312T1 (OSRAM)
TN (1) TN2014000059A1 (OSRAM)
TW (1) TW201316987A (OSRAM)
UY (1) UY34315A (OSRAM)
WO (2) WO2013036563A1 (OSRAM)
ZA (1) ZA201401040B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180030254A (ko) * 2011-09-08 2018-03-21 노파르티스 아게 생식선기능저하증 및 관련 질환의 치료를 위한 아로마타제 억제제의 용도
WO2015148549A1 (en) * 2014-03-26 2015-10-01 The Regents Of The University Of California Ultrasensitive androgen receptor bioassay
PH12016502540B1 (en) * 2014-07-07 2022-07-20 Recordati Ag Pharmaceutical dosage forms
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
WO2018165145A1 (en) * 2017-03-08 2018-09-13 Ariad Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4-[2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl} pyrimidine-2,4-diamine
USD894149S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
USD894148S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
JP7121999B2 (ja) * 2019-09-26 2022-08-19 学校法人九州文化学園 男性性腺機能低下症治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
TW210334B (OSRAM) * 1990-12-12 1993-08-01 Ciba Geigy Ag
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
WO2002002113A1 (en) * 2000-07-05 2002-01-10 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
JP2004526764A (ja) 2001-04-17 2004-09-02 アレス トレーディング ソシエテ アノニム 補助生殖を増強するためのアロマターゼ阻害剤
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
EP1492515A1 (en) * 2002-04-03 2005-01-05 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
WO2006114702A2 (en) * 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CN102335269B (zh) * 2007-11-21 2013-06-19 客乐谐制药株式会社 芳香酶抑制剂
KR20180030254A (ko) * 2011-09-08 2018-03-21 노파르티스 아게 생식선기능저하증 및 관련 질환의 치료를 위한 아로마타제 억제제의 용도

Also Published As

Publication number Publication date
RU2014113575A (ru) 2015-10-20
CL2014000552A1 (es) 2014-09-12
CA2845929A1 (en) 2013-03-14
US20140309267A1 (en) 2014-10-16
PL2753313T3 (pl) 2017-07-31
CN103796644A (zh) 2014-05-14
EP2753313A1 (en) 2014-07-16
JP2014526465A (ja) 2014-10-06
CN103781476A (zh) 2014-05-07
TW201316987A (zh) 2013-05-01
KR20140071358A (ko) 2014-06-11
MX2014002780A (es) 2014-06-05
CY1118499T1 (el) 2017-07-12
SG2014012132A (en) 2014-06-27
SI2753312T1 (sl) 2017-10-30
JP6280501B2 (ja) 2018-02-14
ES2613666T3 (es) 2017-05-25
MX2014002773A (es) 2014-06-05
LT2753312T (lt) 2017-01-25
AU2012304693B2 (en) 2016-03-31
AU2012304693A1 (en) 2014-03-13
EP2753312A1 (en) 2014-07-16
KR20140058619A (ko) 2014-05-14
US9295668B2 (en) 2016-03-29
IL231234A (en) 2016-12-29
CY1118461T1 (el) 2017-07-12
TN2014000059A1 (en) 2015-07-01
WO2013036563A1 (en) 2013-03-14
BR112014004879B1 (pt) 2020-01-28
CN103796644B (zh) 2017-05-03
WO2013036562A1 (en) 2013-03-14
BR112014005434B1 (pt) 2021-01-05
US20160346257A1 (en) 2016-12-01
EP2753312B1 (en) 2016-12-14
US9750724B2 (en) 2017-09-05
CA2846884C (en) 2019-04-09
NZ621476A (en) 2016-02-26
AU2012304694A1 (en) 2014-03-20
CN103781476B (zh) 2016-12-07
BR112014004879A2 (pt) 2017-03-14
AU2012304694B2 (en) 2016-04-07
HUE031478T2 (hu) 2017-07-28
LT2753313T (lt) 2017-02-10
MX343902B (es) 2016-11-28
PL2753312T3 (pl) 2017-06-30
MX360315B (es) 2018-10-29
DK2753312T3 (da) 2017-02-13
HRP20170003T1 (hr) 2017-03-10
PH12014500435A1 (en) 2019-03-22
RU2628808C2 (ru) 2017-08-22
JP6051467B2 (ja) 2016-12-27
EP2753313B1 (en) 2016-12-14
US20160243084A1 (en) 2016-08-25
KR20180030254A (ko) 2018-03-21
RU2617510C2 (ru) 2017-04-25
ZA201401040B (en) 2015-12-23
ES2613667T3 (es) 2017-05-25
US20140213622A1 (en) 2014-07-31
SI2753313T1 (sl) 2017-04-26
IL231234A0 (en) 2014-04-30
PT2753312T (pt) 2017-02-03
KR101872561B1 (ko) 2018-06-28
AR087790A1 (es) 2014-04-16
CA2845929C (en) 2018-06-19
BR112014005434A2 (pt) 2017-04-04
IN2014DN01619A (OSRAM) 2015-05-15
US10064844B2 (en) 2018-09-04
SG10201607503WA (en) 2016-10-28
JP2014528932A (ja) 2014-10-30
CA2846884A1 (en) 2013-03-14
US9370505B2 (en) 2016-06-21
HRP20170002T1 (hr) 2017-02-24
PE20141584A1 (es) 2014-11-13
DK2753313T3 (en) 2017-02-13
RU2014113334A (ru) 2015-10-20
HUE031435T2 (en) 2017-07-28
PT2753313T (pt) 2017-02-02

Similar Documents

Publication Publication Date Title
NI201700034A (es) Indazoles sustituidos con benzilo como inhibidores de bub1.
UY34315A (es) ?uso de un inhibidor de aromatasa para el tratamiento de hipogonadismo y enfermedades relacionadas ?
AR089993A1 (es) Macrociclos peptidomimeticos
UY34401A (es) Métodos para el tratamiento de hcv
MX2021000007A (es) Formulaciones de enzalutamida.
UY34402A (es) Métodos para el tratamiento de hcv
MX2013015311A (es) Polipeptidos de enlace de pcsk9 y metodos de uso.
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
ECSP14013284A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX2013011479A (es) Anticuerpos anti-fgfr4 y metodos de uso.
UY34764A (es) Derivados de 2,2-difluoropropionamida de metilo de bardoxolona, formas polimórficas y sus métodos de uso
BR112013027716A2 (pt) gavetas rápidas com rolos e rampa
BR112013025006A2 (pt) composições e métodos para inibição de expressão do gene tmprss6
CO7091177A2 (es) Inhibidores de la beta-secretasa
UY34365A (es) Compuestos heterociclicos
BR112014026926A2 (pt) uso terapêutico de produtos de semente de chardonnay
CO6801724A2 (es) Composiciones y métodos para el tratamiento de la mielofibrosis
UY34616A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
UY34243A (es) Marcadores y metodos para evaluación del riesgo de enfermedades cardiovasculares
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
IN2014DN09450A (OSRAM)
MX2014015039A (es) Inhibidores de fbx03.
GT201500143A (es) Composiciones que comprenden vortioxetina y donepezilo campo tecnico
BR112013032005A2 (pt) método e dispositivo para obtenção da frêquencia de uso de um programa aplicativo

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020